Ortin Global Limited is an India-based company, which is engaged in the manufacturing and trading of pharmaceuticals, drugs and intermediates, to manufacture, sell or export all types of medicines, including ayurvedic, homeopathic, Unani, biochemical, nature cure and others. The Company is also engaged in the real estate business.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-11-06	₹13.00	0.00%	233
26-11-05	₹13.00	+3.83%	100
26-11-03	₹12.52	-6.22%	90

Delayed Quote Bombay S.E.

More quotes

Delayed Bombay S.E. 01:22:23 2026-11-06 EST			5-day change	1st Jan Change
13.00 ^INR	0.00%		-2.62%	-8.96%

10-01	Ortin Global Limited Approves Managing Director Changes	CI
10-01	Ortin Global Limited Approves Board Changes	CI

Market Cap	106M 1.12M 997K 912K 830K 1.57M 1.61M 10.95M 4.38M 55.98M 4.2M 4.11M 177M	P/E 2025	-9.59x	P/E 2026	-15.5x
Enterprise Value	110M 1.16M 1.03M 946K 862K 1.62M 1.67M 11.37M 4.55M 58.1M 4.36M 4.26M 183M	EV / Sales 2025	23.3x	EV / Sales 2026	110x
Free-Float	79.54%	Yield 2025 *	-	Yield 2026	-

Markets		Quality
Bombay S.E.	ORTINGLOBE	Delayed
NSE India S.E.	ORTINGLOBE	Delayed

10-01	Ortin Global Limited Approves Managing Director Changes	CI
10-01	Ortin Global Limited Approves Board Changes	CI
09-07	Ortin Global Limited Announces Resignation of Prakruti Prashant Sawant as Whole-Time Director, Effective September 7, 2026	CI
08-14	Ortin Global Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
06-17	Parveen Satija completed the acquisition of 0.003% stake in Ortin Global Limited for INR 3311.	CI
05-30	Ortin Global Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
02-14	Ortin Global Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
02-10	Parveen Satija proposed to acquire 26% stake in Ortin Global Limited for INR 31 million.	CI
11-14	Ortin Global to incorporate wholly owned subsidiary in Dubai	RE
11-14	Otin Global Limited Announces Incorporation	CI
11-14	Ortin Global Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
25-09-08	Ortin Global Limited Announces Resignation of Sashikant Shankarrao Igave as Non-Executive Non-Independent Director, Effective September 8, 2025	CI
25-08-25	Ortin Global Limited Approves Board Appointments	CI

Ortin Global Limited Stock

Stocks

ORTINGLOBE

INE749B01020

Pharmaceuticals

Valuation: Ortin Global Limited

Chart: Ortin Global Limited

Latest news: Ortin Global Limited

Press Releases: Ortin Global Limited

Quotes and Performance

Price Extremes

Managers and Directors: Ortin Global Limited

Other Pharmaceuticals

Financials

Company Profile

Quotes

25-10-03	ORTELIUS AB (formerly ORTELIUS International AB) – Half-Year Results for the First Half of 2025	AQ
25-10-02	ORTELIUS International AB officially listed under its own name	AQ

1 week	-2.62%
Current month	+7.00%
1 month	-10.34%
3 months	-14.75%
6 months	-10.16%
Current year	-8.96%

1 week	11.46	13.35
1 month	11.46	15.38
Current year	11.46	21.15
1 year	11.21	21.15
3 years	9.57	26.39
5 years	9.57	38.35
10 years	9.57	71.67

Manager	Title	Age	Since
Prashant Prakash Sawant CEO	Chief Executive Officer	-	2026-09-06
Wani Rahul Madanla DFI	Director of Finance/CFO	-	2025-07-10
Madhu Mala Solanki CMP	Compliance Officer	-	2025-03-31

Director	Title	Age	Since
Murali Krishna M. Sanka BRD	Director/Board Member	-	-
Mounika Reddy Pammi BRD	Director/Board Member	43	2025-05-25
Pramod Dnyandeo Waghe BRD	Director/Board Member	-	2023-11-03

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORTIN GLOBAL LIMITED	0.00%	-2.62%	+10.26%	-26.26%	1.12M
ELI LILLY AND COMPANY	-3.76%	-0.65%	+47.41%	+140.35%	1,216B
JOHNSON & JOHNSON	-1.45%	-1.05%	+46.41%	+79.94%	656B
ABBVIE INC.	-2.24%	-0.88%	+32.97%	+103.82%	509B
ROCHE HOLDING AG	-1.95%	-4.59%	+45.14%	+62.30%	384B
MERCK & CO., INC.	-2.27%	+0.42%	+74.12%	+42.14%	362B
NOVARTIS AG	-2.24%	-2.02%	+28.61%	+55.60%	311B
ASTRAZENECA PLC	-2.84%	-2.29%	+6.28%	+32.74%	293B
AMGEN INC.	-3.80%	-0.10%	+43.90%	+70.56%	249B
GILEAD SCIENCES, INC.	-3.96%	+1.18%	+36.70%	+105.38%	208B
Average	-2.45%	+0.54%	+37.18%	+66.66%	418.78B
Weighted average by Cap.	-2.75%	+0.03%	+42.58%	+91.09%

	2025	2026
Net sales	3.42M 36.24K 32.3K 29.54K 26.9K 50.71K 52.08K 355K 142K 1.81M 136K 133K 5.72M	1.08M 11.47K 10.22K 9.35K 8.51K 16.05K 16.48K 112K 44.91K 574K 43.06K 42.13K 1.81M
Net income	-8.46M -89.57K -79.81K -73K -66.48K -125K -129K -877K -351K -4.48M -336K -329K -14.14M	-7.4M -78.35K -69.82K -63.86K -58.16K -110K -113K -767K -307K -3.92M -294K -288K -12.37M
Net Debt	-1.24M -13.09K -11.66K -10.67K -9.72K -18.32K -18.81K -128K -51.25K -655K -49.13K -48.08K -2.07M	3.99M 42.23K 37.63K 34.42K 31.35K 59.09K 60.68K 414K 165K 2.11M 159K 155K 6.67M